Sign In
Buy INCY
$97.98
+5.74 (+6.22%)
At Close: Jun 03, 2026
Eli Lilly and Incyte's Olumiant Helps Eczema Patients in a Late-Stage Clinical Trial
06:08pm, Monday, 27'th Jan 2020
The results could help expand use of the drug that's currently approved to treat rheumatoid arthritis.
3 Biotech Stocks Nearing Support
09:08am, Monday, 27'th Jan 2020
Pricing concerns have resurfaced among biotech stocks this month. The recent pullback could offer a buying opportunity.
Incyte Stock Is Down: Buy the Dip?
09:00am, Wednesday, 15'th Jan 2020
Incyte's reliance on one product might be an issue.
2 Top Growth Stocks to Buy in January
07:00am, Wednesday, 15'th Jan 2020
Two pharma stocks, one riding a wave of enthusiasm and one getting unfairly punished, look appealing from a long-term standpoint.
Incyte (INCY) Stock Sinks As Market Gains: What You Should Know
05:50pm, Wednesday, 08'th Jan 2020
Incyte (INCY) closed at $76.53 in the latest trading session, marking a -0.79% move from the prior day.
Incyte's Application for Pemigatinib Gets EMA's Validation
11:26am, Wednesday, 08'th Jan 2020
The EMA endorses Incyte's (INCY) MAA for pemigatinib to treat locally advanced/metastatic cholangiocarcinoma with a FGFR2 fusion that is relapsed or refractory post minimum one line of systemic therap
Better Buy: Geron vs. Incyte
09:45am, Tuesday, 07'th Jan 2020
Formed in the early ‘90s, Geron and Incyte exemplify the long and often tumultuous road it takes to translate science into medicines.
Incyte: Looking More Appealing, Yet Pipeline Conversion Is Required
12:09am, Monday, 06'th Jan 2020
Incyte has seen a continued increase in sales, yet real diversification efforts have not paid off just yet.
Incyte News: INCY Stock Tumbles 10% on Experimental Drug Study Failure
03:46pm, Friday, 03'rd Jan 2020
Incyte (INCY) news for Friday about a recent clinical trial failing to meet its endpoints has INCY stock taking a beating.
The post Incyte News: INCY Stock Tumbles 10% on Experimental Drug Study Failu
Here's Why Incyte Fell as Much as 12.6% Today
11:47am, Friday, 03'rd Jan 2020
An important clinical trial failed, reminding investors of the company's poor track record with its pipeline.
Incyte Stock Pummeled As Late-Stage Failure Casts Doubt On Pipeline
11:24am, Friday, 03'rd Jan 2020
Incyte stock tumbled to a three-month low Friday amid a flurry of price-target cuts following the biotech company's late-stage failure in never-before-treated acute graft vs. host disease.
Incyte's (INCY) Itacitinib Fails in Late-Stage GVHD Study
10:01am, Friday, 03'rd Jan 2020
Incyte (INCY) fails to meet goals in the phase III study on itacitinib for the treatment of first-line acute GVHD.
Leading Biotech Stock Crashes After Promising Drug Fails Late-Stage Test
05:29pm, Thursday, 02'nd Jan 2020
Incyte stock crashed late Thursday after the biotech company's treatment for never-before-treated patients with graft vs. host disease, a transplant complication, failed in a study.
Incyte stock slammed after study fails to hit goal
04:40pm, Thursday, 02'nd Jan 2020
Incyte Corp. INCY, -1.55% shares fell more than 12% in after-hours trading Thursday after the company revealed that a phase-3 study of a drug failed to reach its goal.
A $20 Billion Sweet Spot in Biotech
08:00am, Saturday, 28'th Dec 2019
Few biotech companies ever reach that valuation, and if they do, you should snap them up for your portfolio.
